Compare ESPR & SMWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESPR | SMWB |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 660.1M | 747.7M |
| IPO Year | 2013 | 2021 |
| Metric | ESPR | SMWB |
|---|---|---|
| Price | $3.70 | $7.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $6.86 | ★ $14.88 |
| AVG Volume (30 Days) | ★ 7.0M | 416.0K |
| Earning Date | 11-06-2025 | 11-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $303,802,000.00 | $275,429,000.00 |
| Revenue This Year | $25.45 | $16.89 |
| Revenue Next Year | N/A | $14.52 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 2.83 | ★ 14.25 |
| 52 Week Low | $0.69 | $6.36 |
| 52 Week High | $4.03 | $17.64 |
| Indicator | ESPR | SMWB |
|---|---|---|
| Relative Strength Index (RSI) | 63.61 | 43.19 |
| Support Level | $3.59 | $7.55 |
| Resistance Level | $3.91 | $7.93 |
| Average True Range (ATR) | 0.24 | 0.36 |
| MACD | 0.05 | 0.06 |
| Stochastic Oscillator | 77.74 | 54.32 |
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
Similarweb Ltd provides digital data and analytics that power critical business decisions. The group recognizes revenue from subscriptions to the platform and other subscription products on a straight-line basis over the term of the contract subscription period beginning on the date access to the platform is granted, provided all other revenue recognition criteria have been met. It has geographic presence in Israel, the United States, the United Kingdom, Asia Pacific, Europe, and Other. The group generates the majority of its revenue from the United States.